Video

SMARTag™ ADC Technology

Source: Catalent

SMARTag™ ADC technology enables biologic innovators to develop more efficacious antibody drug conjugates faster. This platform leverages Catalent’s biologic drug development expertise, advanced GPEx® expression system, clinical biomanufacturing and integrated services, offering a number of advantages to ADC developers.

Learn more about:

  • Site-Specific, Programmable Drug Placement.
  • Cytotoxin/Linker & Conjugation Technologies.
  • Efficient & Scalable Process.

<iframe src="https://www.biosimilardevelopment.com/player/a4bfd828-70b2-481d-b5f2-9ff86d6fe1dc" style="height:390px; width:600px;" frameborder="0"></iframe>